Your browser doesn't support javascript.
loading
Morbidity and Functional Outcomes Following Rocky Mountain Spotted Fever Hospitalization-Arizona, 2002-2017.
Drexler, Naomi A; Close, Ryan; Yaglom, Hayley D; Traeger, Marc; Parker, Kristen; Venkat, Heather; Villarroel, Lisa; Brislan, Jeanette; Pastula, Daniel M; Armstrong, Paige A.
Afiliación
  • Drexler NA; Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Close R; Whiteriver Indian Hospital, Indian Health Service, Whiteriver, Arizona, USA.
  • Yaglom HD; Pathogen and Microbiome Division, Translational Genomics Research Institute, Flagstaff, Arizona, USA.
  • Traeger M; Office of Infectious Disease Services, Arizona Department of Health Services, Phoenix, Arizona, USA.
  • Parker K; Whiteriver Indian Hospital, Indian Health Service, Whiteriver, Arizona, USA.
  • Venkat H; Whiteriver Indian Hospital, Indian Health Service, Whiteriver, Arizona, USA.
  • Villarroel L; Office of Infectious Disease Services, Arizona Department of Health Services, Phoenix, Arizona, USA.
  • Brislan J; Center for Preparedness and Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Pastula DM; Office of Infectious Disease Services, Arizona Department of Health Services, Phoenix, Arizona, USA.
  • Armstrong PA; Gila River Healthcare Public Health Nursing, Sacaton, Arizona, USA.
Open Forum Infect Dis ; 9(10): ofac506, 2022 Oct.
Article en En | MEDLINE | ID: mdl-36324320
ABSTRACT

Background:

Rocky Mountain spotted fever (RMSF) is a deadly tickborne disease disproportionately affecting Arizona tribal communities. While the acute clinical effects of RMSF are well-documented, more complete understanding of the long-term health consequences is needed to provide guidance for providers and patients in highly impacted areas.

Methods:

We performed a retrospective review of hospitalized RMSF cases from 2 tribal communities in Arizona during 2002-2017. Medical records from acute illness were abstracted for information on clinical presentation, treatment, and status at discharge. Surviving patients were interviewed about disease recovery, and patients reporting incomplete recovery were eligible for a neurologic examination.

Results:

Eighty hospitalized cases of RMSF met our inclusion criteria and were reviewed. Of these, 17 (21%) resulted in a fatal outcome. Among surviving cases who were interviewed, most (62%) reported full recovery, 15 (38%) reported ongoing symptoms or reduced function following RMSF illness, and 9 (23%) had evidence of neurologic sequelae at the time of examination. Sequelae included impaired cognition, weakness, decreased deep tendon reflexes, seizures, and cranial nerve dysfunction. Longer hospitalization (25.5 days vs 6.2 days, P < .001), a higher degree of disability at discharge (median modified Rankin score 1 vs 0, P = .03), and delayed doxycycline administration (6.2 days vs 4.1 days, P = .12) were associated with long-term sequelae by logistic regression.

Conclusions:

Although the etiology of sequelae is not able to be determined using this study design, life-altering sequelae were common among patients surviving severe RMSF illness. Delayed administration of the antibiotic doxycycline after day 5 was the strongest predictor of morbidity.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline / Prognostic_studies Idioma: En Revista: Open Forum Infect Dis Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline / Prognostic_studies Idioma: En Revista: Open Forum Infect Dis Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos